FDA Historical Calendar

TickerCurrent price52 hi52 loProductIndicationPDUFA dateDecisionNotes
TSX:PLBImpavidoTropical disease leishmaniasis3/19/2014ApprovedApproved Mar 19
BMY30.9257.4939.18Eliquis To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
PFE30.9232.9627.12EliquisTo Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
ENDP62.0282.1632.66AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadism3/28/2014ApprovedApproved March 6 2014
AZN67.7869.6546.87MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
BMY50.9557.4939.18MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
CHTP5.056.831.68NORTHERA Neurogenic Orthostatic HypotensionApprovedApprovedApproved one day late due to snow
BMRN75.8184.2553.53Vimizim (GALNS)(MPS IVA) Morquio A Syndrome2/28/2014Approved Early approval. Was under priority review
DRRX1.352.690.76PosidurPost-operative pain relief 2/12/2014CRL
PCYC93.61154.8974.36Ibrutinib Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy2/28/2014ApprovedApproved Feb 12 2014
VNDA14.6119.254.63HETLIOZ (tasimelteon)Non-24-Hour Sleep-Wake Disorder1/31/2014Approved
VRX133.23153.1071.99Retin-A Micro (tretinoin) Gel microsphere 0.08% Acne vulgarisApprovedsNDA
AMAG18.3628.4216.49FerahemeIron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to all adult patients with IDA who have failed or could not tolerate oral iron treatment1/21/2014CRLOriginal PDUFA date delayed
NRIFF3.315.201.26Pennsaid 2%Pain of osteoarthritis of the knee2/7/2014ApprovedApproved Jan 17 2014
AZN67.7869.6546.87FARXIGA (dapagliflozin) tablets Adult patients with type 2 diabetesApproved
BMY50.9557.4939.18FARXIGA (dapagliflozin) tabletsAdult patients with type 2 diabetesApproved
GSK55.1456.7348.30Mekinist (trametinib) and Tafinlar (dabrafenib)Unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutationsApprovedAccelerated approval based on Phase 2 trial. Approval coningent on Phase 3 trial outcome
MRK57.5058.3244.60ISENTRESS for oral suspensionHIV-1 infected infants and childrenApproved
AZN67.7869.6546.87Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
BMY50.9557.4939.18Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
SNY53.1755.9446.95LemtradaRelapsing forms of multiple sclerosis.CRLCRL 29/12/13
UTHR93.63116.6559.05Oral treprostinilPulmonary arterial hypertension (PAH)2/16/2014ApprovedApproved Dec 20 2013. Early approval following previous extension
THRX27.0742.9626.04UMEC/VI (62.5/25mcg and 125/25mcg doses) ANORO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)12/18/2013ApprovedApproved Dec 18 2013
JNJ100.22100.7582.12Canagliflozin and immediate-release metforminAdults with type 2 diabetesCRL
GILD73.8684.8846.70Sovaldi (Sofosbuvir)HCV6/12/2013Approved
AUXL27.5332.8913.87XIAFLEXPeyronie’s6/12/2013ApprovedApproved Dec 6 2013
PCYC93.61154.8974.36Ibrutinib versus temsirolimus - RAY (MCL3001)Cancer - relapsed or refractory MCL mantle cell lymphoma2/28/2013Approved Approved Nov 13 2013, 3 months early. Was under priority review
ZGNX2.815.191.25Zohydro ERModerate to severe painApprovedApproved Oct 25 2013. Decision was delayed by several months
AGN165.65166.0081.33JUVÉDERM VOLUMA XCAge-related volume loss in the cheek area in adults over the age of 21ApprovedApproved Oct 23 2013
ALIOF76.16106.1257.10Macitentan (Opsumit)Pulmonary arterial hypertension10/18/2013ApprovedApproved Oct 18 2013
ALIM6.118.441.65IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
PSDV3.675.602.12IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
ATRS4.365.152.70OTREXUPRheumatoid arthritis (RA)10/14/2013ApprovedApproved Oct 14 2013
DCTH3.8326.243.53CHEMOSAT systemCancer - unresectable metastatic ocular melanoma in the liver9/13/2013CRL CRL Sept 13 2013
CELG144.82174.66110.53ABRAXANEMetastatic pancreatic cancer9/21/2013ApprovedApproved Sep 6 2013
QRXPY0.566.880.42MOXDUOModerate to severe acute pain8/26/2013CRLCRL Aug 2013. Expects to resubmit 4Q 2013. Expects Adcom meeting
SUPN8.0610.554.45Trokendi XR SPN-538EpilepsyApprovedApproved Aug 19 2013
JNJ100.22100.7582.12SIMPONI ARIARheumatoid ArthritisApprovedApproved Jul 18 2013
MRK46.3258.3244.60Suvorexant tabletsInsomniaCRLAdcom May 22 2013. 13-3 positive vote. CRL received Jul 1 2013
GSK55.1456.7348.30Dolutegravir - ViiV HealthcareHIV8/17/2013ApprovedPDUFA Aug 12 under priority review.
JNJ100.22100.7582.12XARELTO (rivaroxaban)Stent Thrombosis in Patients with Acute Coronary SyndromeCRLCRL issued Jun 28 2013
THRX113.3242.9626.04VIBATIV (telavancin hydrochloride) for injectionHospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)ApprovedApproved Jun 21 2013
AMGN27.07128.9694.15XGEVACancer - Giant Cell Tumor Of BoneApprovedApproved 6/13/13
AVEO1.338.401.27TivozanibCancer - advanced renal cell carcinoma7/28/2013CRLNegative 1-13 vote at Adcom meeting May 2 2013.Early CRL Jun 10 2013
CELG144.82174.66110.53REVLIMIDCancer - relapsed/refractory mantle cell lymphomaApproved Approved Jun 5 2013 under priority review
FLML11.5014.954.10Bloxiverz (neostigmine methylsulfate)Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery5/31/2013ApprovedApproved Jun 3 2013
DEPO5.7615.394.99SEFELSAHot flashes5/31/2013CRLCRL May 31 2013
ENDP62.0282.1632.66AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadismCRLCRL issued May 30 2013. Expects to respond 3Q 2013
GSK55.1456.7348.30DabrafenibCancer - melanoma6/3/2013Approved Approved May 29 2013
GSK55.1456.7348.30TrametinibCancer - melanoma6/3/2013ApprovedApproved May 29 2013
VRX133.23153.1071.99EfinaconazoleOnychomycosis5/24/2013CRLCRL May 28 2013
JNJ100.22100.7582.12SIMPONI (golimumab) ulcerative colitis (UC)ApprovedApproved May 16
THRX27.0742.9626.04BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
GSK55.1456.7348.30BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
BMY50.9557.4939.18SUSTIVA® (efavirenz)HIV-1ApprovedsNDA approved May 3 2013
MRK57.5058.3244.60LIPTRUZET (ezetimibe and atorvastatin)LDL CholesterolApprovedApproved May 3 2013
SHPG164.20172.2786.01Vyvanse® (lisdexamfetamine dimesylate) Children and Adolescents with ADHD5/1/2013ApprovedApproved May 1 2013
TTNP0.601.990.32ProbuphineOpioid dependence4/30/2013CRLCRL issued midnight Apr 30
RPTP8.2717.725.50DR CysteamineCystinosis4/30/2013ApprovedApproved Apr 30, 2013.
GILD73.8684.8846.70ElvitegravirHIV4/27/2013CRLCRL Apr 29 2013
GILD73.8684.8846.70CobicistatHIV4/28/2013CRLCRL Apr 29 2013
WCRX0.00#N/A#N/AMINASTRINContraceptiveApprovedApproved Apr 22 2013
SCMP6.7611.005.40Amitiza/ LubiprostoneOpioid-induced bowel dysfunction4/24/2013ApprovedApproved Apr 23 2013
NVS86.1786.9767.67Simbrinza(TM) SuspensionGlaucomaApprovedApproved Apr 19 2013
JNJ100.22100.7582.12InvokanaType 2 diabetes3/31/2013ApprovedApproved Mar 29 2013
APPA#N/A#N/A#N/AAPF530Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)3/27/2013CRLCRL Mar 28 2013
UTHR93.63116.6559.05Treprostinil diolamine extended release tablets (oral treprostinil)Pulmonary arterial hypertension3/31/2013CRLCRL Mar 25, 6 days early
NAVB1.733.311.11LymphoseekLymphatic-tissue tracing agent4/30/2013Approved Approved Mar 13 2013. 7 weeks early.
JNJ100.22100.7582.12XARELTOReduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS)3/5/2013CRLCRL March 5 2013
ONXX0.00#N/A#N/AStivargaMetastatic and/or unresectable gastrointestinal stromal tumors (GIST)2/25/2013ApprovedApproved Feb 25 2013
DVAX1.582.680.98HEPLISAVHepatitis B2/24/2013CRLCRL Feb 25 2013. Hopes to meet with FDA by mid April to discuss CRL
IMGN13.9020.2511.78KadcylaCancer - 2nd-line HER2+ Metastatic Breast Cancer2/26/2013ApprovedApproved Feb 22 2013 - under priority review
NVS86.1786.9767.67Zortress (everolimus)Prevent organ rejection in adult liver transplant patientsApprovedApproved Feb 15 2013
CELG144.82174.66110.53PomalystCancer - Multiple Myeloma2/10/2013ApprovedApproved Feb 8 2013
HEB0.360.550.19Ampligen CFS2/4/2013CRLCRL Feb 4 2012. Resubmission. More trials required. Intends to appeal
HPTX25.6132.9815.92RavictiUrea cycle disorders1/22/2013ApprovedApproved Feb 1 2013. FDA had advised company of delay
FURX81.19121.9732.01AlogliptinDiabetes - Type 21/27/2013Approved NDA resubmitted July 27 2012, following CRL. Approved Jan 25 2013
IPXL26.2728.5016.09IPX066Parkinson's 1/21/2013CRLCRL January 21 2013
PATH0.00#N/A#N/AZecuity Migraine1/17/2013ApprovedApproved Jan 17 2013
SNTS0.00#N/A#N/ABudesonideUCERIS (Budesonide)Ulcerative colitis disease1/16/2013ApprovedApproved Jan 14 2013, two days early
AEGR43.92101.0037.26LomitapideHomozygous familial hypercholesterolemia (HoFH)1/6/2013ApprovedEarly approval Dec 24 2012
ALXA4.336.653.92Staccato loxapine (ADASUVE). Schizophrenia12/21/2012Approved
NPSP25.8839.6812.43GattexShort bowel syndrome or SBS12/30/2012ApprovedPDUFA date was Dec 30 2012. Early approval on Dec 21
ARIA7.5023.002.15Oral ponatinibCancer - chronic myeloid leukemia, acute lymphoblastic leukemia3/27/2013ApprovedPDUFA March 27 2013. Early approval Dec 14 2012 under priority review
EXEL3.458.413.02CabozantinibCancer - Medullary thyroid 11/29/2012ApprovedApproved Nov 29 2012 under priority review
LGND69.1880.4225.60Promacta/RevoladeThrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C11/30/2012ApprovedApproved Nov 19 2012 under priority review, 11 days prior to PDUFA date
CRTX0.00#N/A#N/ACRTX 080Hyponatremia10/29/2012CRLAdditional clinical and non-clinical information required
SUPN8.0610.554.45OxtellarEpilepsy10/22/2012Approved
NAVB1.733.311.11LymphoseekLymphatic-tissue tracing agent9/10/2012CRL3rd party manufacturing deficiencies cited
MDVN60.0488.2044.51MDV3100Cancer - prostate 2nd line8/31/2012Approved Early approval decision by 3mths approx. Was under priority review
TLON0.161.830.13Marqibo2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)8/12/2012Approved Approved 8/9/2012
HALO7.5918.185.68HyQPrimary immunodeficiency diseaseCRL
PGNX/SLXP3.72#N/A#N/ASubcutaneous RELISTORchronic pain7/27/2012CRLPrice shown is for PGNX
AMRN1.627.981.36Vascepa Elevated triglyceride levels7/26/2012Approved
HZNP14.4018.302.11LODOTRA (RAYOS)Rheumetoid Arthritis7/26/2012Approved
ONXX/LGND0.00#N/A#N/ACarfilzomibMultiple myeloma7/20/2012ApprovedPrice shown is for ONXX
VVUS5.1215.624.71QnexaObesity7/18/2012Approved
ARNA6.169.254.05LorcaserinObesity6/27/2012Approved
QRX0.121.340.12MOXDUOModerate to severe acute pain6/26/2012CRL
RGEN15.8417.267.37RG1068Detection of pancreatic duct abnormalities6/22/2012CRL
XNPT4.427.453.89HorizantPostherpetic Neuralgia6/9/2012Approved
ARIA7.5023.002.15RidaforolimusSoft tissue or bone sarcoma6/6/2012CRL
EBS26.5028.4813.88BioThraxAnthrax Vaccine5/17/2012ApprovedApproved May 17 2012
TLON0.161.830.13MarqiboPhiladelphia chromosome-negative acute lymphoblastic leukemia 5/13/2012Extended
ALXA4.336.653.92ADASUVESchizophrenia5/3/2012CRL
PLX4.175.813.70Taliglucerase alfa Gaucher disease5/1/2012Approved
VVUS5.1215.624.71AvanafilErectile dysfunction4/29/2012Approved
PGNX/SLXP3.72#N/A#N/ASubcutaneous RELISTORChronic pain4/27/2012ExtendedPrice shown is for PGNX
FURX81.19121.9732.01AlogliptinDiabetes - Type 24/25/2012CRL
VVUS5.1215.624.71QnexaObesity4/17/2012Extended
CHTP5.056.831.68NORTHERA Neurogenic Orthostatic Hypotension3/28/2012CRL
AFFY0.642.100.60PeginesatideAnemia in chronic renal failure (CRF)3/27/2012Approved
MAPP0.00#N/A#N/ALevadexMigraine3/26/2012CRL
CRIS2.314.742.09VismodegibBasal Cell Carcinoma3/8/2012ApprovedEarly decision Jan 30,2012
NGSX0.010.020.00QutenzaNeuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN)3/7/2012CRL
DSCO1.963.051.50Surfaxin Respiratory Distress Syndrome - Severe3/6/2012Approved
ASTX0.00#N/A#N/ADacogenAcute myeloid leukemia3/6/2012CRL
CBRX6.728.374.80Progesterone vaginal gelReduction of risk of preterm birth2/26/2012CRL
CORT4.024.491.47Corlux - KorlymCushing's Syndrome2/17/2012Approved
BPAX#N/A#N/A#N/ABio-T-GelMale hypogonadism2/14/2012Approved
ALXA4.336.653.92ADASUVESchizophrenia2/4/2012Extended 3months
AMLN0.00#N/A#N/ABYDUREONType 2 diabetes1/28/2012Approved
ALKS46.7754.2526.47BYDUREONType 2 diabetes1/28/2012Approved
PLX4.175.813.70Taliglucerase alfa Gaucher disease1/2/2012Extended 3 monthsInformed Dec 6 2011
NEOL#N/A#N/A#N/ASUBSYSCancer pain1/1/2012Approved
AIS2.94142.70128.00AnturolOveractive bladder12/8/2011ApprovedChanged ticker to ATRS
INCY46.9670.8618.23JakafiMyelofibrosis12/3/2011ApprovedApproved Nov 16 2011
TSPT2.994.232.52IntermezzoInsomnia11/27/2011Approved
SPPI7.1810.326.36Removal of the Bioscan Requirement for ZevalinNon-Hodgkin's lymphoma11/20/2011Approved
ALIM/PSDV6.11#N/A#N/AILUVIENDiabetic macular edema11/12/2011CRLEarly CRL. Price shown is for ALIM
IGXT0.921.180.47CPI-300Major Depressive Disorder11/10/2011Approved
PCRX68.3083.4124.70EXPARELPostsurgical pain10/28/2011Approved
SGEN39.7955.9928.15ADCETRISHodgkin lymphoma8/30/2011Approved
SGEN39.7955.9928.15ADCETRISAnaplastic large cell lymphoma8/30/2011Approved
PATH0.00#N/A#N/AZelrixMigraine8/29/2011CRL
ANX2,240.002,382.001,931.00ExelbineNSCLC8/9/2011CRL
TSPT2.994.232.52IntermezzoInsomnia7/14/2011CRL
PTIE/DRXX5.69#N/A#N/AREMOXYModerate to severe pain6/23/2011CRLPrice shown is for PTIE
FCSC4.047.203.28LavivWrinkles6/22/2011Approved
ACUR1.372.881.17OxectaPain relief6/17/2011Approved
OPTR0.00#N/A#N/AFidaxomicinCDI - diarrhea5/30/2011Approved
SPPI7.1810.326.36FUSILEVColorectal cancer4/29/2011Approved
XNPT4.427.453.89HorizantRestless Legs Syndrome4/6/2011Approved
HGSI0.00#N/A#N/ABENLYSTALupus3/10/2011Approved
PLX4.175.813.70Taliglucerase alfa Gaucher disease2/25/2011CRL
OREX5.547.844.59ContraveObesity1/31/2011CRL
DEPO13.2115.394.99GRALISEPostherpetic neuralgia - shingles1/30/2011Approved
MNKD6.368.703.76AfrezzaInsulin1/26/2011CRLEarly CRL
CLDA#N/A#N/A#N/AViibrydMajor depressive disorder1/23/2011ApprovedAcquired by Forest Laboratories (FRX)
PSDV/ALIM6.11#N/A#N/AILUVIENDiabetic macular edema12/29/2010CRLEarly CRL. Price shown is for ALIM
CADX0.00#N/A#N/AOFIRMEVPain and fever11/4/2010Approved
BIOD2.466.081.93VIAjectDiabetes10/30/2010CRL
AVNR3.476.002.62NUEDEXTAPseudobulbar affect10/30/2010Approved
VVUS5.1215.624.71QnexaObesity10/28/2010CRL
ALKS/AMLN46.77#N/A#N/ABYDUREONType 2 diabetes10/22/2010CRLPrice shown is for ALKS
ISTA0.00#N/A#N/ABROMDAYPostoperative inflammation and reduction of ocular pain10/16/2010ApprovedAcquired by Bausch + Lomb
QCOR80.0785.6928.27ActharInfantile spasms10/15/2010Approved
ALXA4.336.653.92ADASUVESchizophrenia10/11/2010CRL
JAZZ143.91176.6053.29JZP-6Fibromyalgia10/11/2010CRL
HGSI0.00#N/A#N/AZALBINHepatitis C10/5/2010CRL
PGNX3.727.453.20RelistorOpioid-induced constipation (OIC)9/29/2010Approved
SVNT#N/A#N/A#N/AKRYSTEXXAGout9/14/2010Approved
QCOR80.0785.6928.27ActharInfantile spasms6/11/2010Extended 4 months
POZN9.229.904.26VIMOVOGastric ulcers4/30/2010Approved
ITMN29.8138.738.86EsbrietIdiopathic pulmonary fibrosis 4/5/2010CRL
SLXP109.95120.0049.33XIFAXANHepatic encephalopathy3/24/2010Approved
CTIC3.184.250.97PixuvriNon-Hodgkin's lymphoma3/23/2010CRL
SOMX3.005.441.29SilenorInsomnia3/19/2010Approved
APPA#N/A#N/A#N/AAPF530Chemotherapy-induced nausea and vomiting3/18/2010CRL
SUPG0.00#N/A#N/ADacogenMyelodysplastic syndromes3/8/2010ApprovedChanged ticker to ASTX
AMLN/ALKS46.77#N/A#N/ABYDUREONType 2 diabetes3/5/2010CRLPrice shown is for ALKS
CRXX1.17#N/A#N/AExalgoModerate to severe pain in opioid tolerant patients3/2/2010ApprovedChanged ticker to ZLCS
CADX0.00#N/A#N/AOFIRMEVPain and fever2/12/2010CRL
DDSS0.13#N/A#N/AOleptroMajor depressive disorder2/11/2010ApprovedBankrupt
XNPT4.427.453.89HorizantRestless Legs Syndrome2/9/2010CRL
PLX4.175.813.70Taliglucerase alfa Gaucher disease2/9/2010Extended
WCRX0.00#N/A#N/AWC 3016Oral contraceptive1/26/2010CRL
ACOR35.2540.8727.51AMPYRAImprove walking in patients with multiple sclerosis1/22/2010Approved
MNKD6.368.703.76AFREZZADiabetes1/16/2010CRLFDA responded 15 Mar 2010
FCSC4.047.203.28LavivWrinkles1/4/2010CRLEarly CRL
VION#N/A#N/A#N/AOnriginAcute myeloid leukemia12/12/2009CRLBankrupt
SOMX3.005.441.29SilenorInsomnia12/4/2009CRL
SNTS0.00#N/A#N/AZEGERIDGERD12/4/2009Approved
DYAX6.8410.992.26KALBITORHereditary angioedema 12/1/2009Approved
NGSX0.010.020.00QutenzaPostherpetic neuralgia11/16/2009Approved
CADX0.00#N/A#N/AOFIRMEVMild to moderate pain11/13/2009Approved
NRIFF3.315.201.26PennsaidOsteoarthritis of the knee11/4/2009Approved
TSPT2.994.232.52IntermezzoInsomnia11/2/2009CRL
GTXI1.407.241.26ToremifeneReduce fractures in men with prostate cancer10/30/2009CRL
SPPI7.1810.326.36FUSILEVColorectal cancer10/8/2009CRL
ALTH0.00#N/A#N/AFOLOTYNPeripheral T-cell lymphoma9/24/2009Approved
ISTA#N/A#N/ABepreveAllergic conjunctivitis9/14/2009ApprovedAcquired by Bausch + Lomb
SPPI7.1810.326.36ZEVALINNon-Hodgkin's Lymphoma 9/7/2009Approved
NGSX0.010.020.00QutenzaPostherpetic neuralgia8/17/2009Extended 3 months
SVNT#N/A#N/A#N/AKRYSTEXXAGout8/3/2009CRL
DDSS0.13#N/A#N/AOleptroMajor depressive disorder7/20/2009CRLBankrupt
ZGNX2.815.191.25SumavelMigraine7/15/2009Approved
ARDM0.220.400.09SumavelMigraine7/15/2009Approved
SPPI7.1810.326.36ZEVALINNHL7/2/2009CRL
HEB0.360.550.19AmpligenChronic fatigue syndrome5/25/2009CRLCRL PR released Dec 1, 2009. PDUFA date was May 25, 2009. FDA advised only of a 1-2 week delay

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.

2 Responses to “FDA Historical Calendar”

  1. Chirag says:

    a thousand thanks !!

Leave a Reply